A randomised placebo-controlled trial of low-dose transdermal estrogen in transgender women during surgery
Safety and quality of life of perioperative transdermal estradiol continuation during gender affirmation surgery in transgender women: a randomised placebo-controlled trial
University of Melbourne
32 participants
Feb 1, 2021
Interventional
Conditions
Summary
Despite no clear evidence, transgender women are told to stop their feminising estrogen treatment several weeks before gender surgery, but can cause severe ‘menopausal symptoms’ with hot flushes, depression and distress compounding an already stressful preparation for and recovery from major surgery. This study will assess the safety of continuing estrogen gel around the time of surgery. We hypothesise that estrogen gel will reduce 'menopause symptoms' and improve quality of life, and will be safe to continue around gender surgery.
Eligibility
Inclusion Criteria1
- Transgender women undergoing gender affirmation surgery (vaginoplasty or labioplasty).
Exclusion Criteria4
- Contraindications to estradiol including estrogen-sensitive malignancy
- History of thromboembolic disease
- Known thrombophilia
- Use of estradiol implant
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Estradiol gel (Estrogel) 2 pump actuations (1.5mg estradiol) transdermally once daily commencing 4 weeks prior to surgery Adherence monitored through unused product return
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12621000022864